Biotech News
Related news
OTLKOutlook2026-08-27 20:05 EST
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
OTLKOutlook2026-10-09 12:30 EST
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
LENZLenz Therapeutics Inc2026-07-06 12:15 EST
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
OCULOcular Therapeutix2026-11-20 12:00 EST
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TARSTarsus Pharmaceuticals2026-10-28 12:30 EST
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
BLTEBelite Bio2026-08-24 20:00 EST
Belite Bio to Host Virtual Commercial Day on September 2, 2026
TARSTarsus Pharmaceuticals2026-07-13 20:05 EST
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
RHHBYRoche Holdings AG2026-10-28 06:00 EST
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
OCGNOcugen2026-11-10 12:00 EST
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
SGHTSight Sciences2026-11-05 13:00 EST
Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
Outlook
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...
Recent company news
OTLKOutlook2026-10-09 12:30 EST
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
OTLKOutlook2026-10-06 13:20 EST
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
OTLKOutlook2026-10-01 13:01 EST
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
OTLKOutlook2026-09-11 11:00 EST
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
OTLKOutlook2026-09-10 13:10 EST
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Stock data
- Close
- 0.40 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
